

INDGN/SE/2024-25/93

January 30, 2025

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

Sub: Press Release regarding financial results for the quarter ended December 31, 2024

We wish to inform you that the Company has made a press release dated January 30, 2025, announcing the financial results for the quarter ended December 31, 2024 as approved by the Board of Directors at its meeting held on January 30, 2025.

A copy of the Press Release is attached for your records.

Please acknowledge the receipt.

Thanking you,

Yours Sincerely,

For Indegene Limited
(Formerly known as Indegene Private Limited)

Srishti Ramesh Kaushik
Company Secretary and Compliance officer



Indegene Limited (Formerly Indegene Private Limited),
Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara,
Bengaluru- 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: U73100KA1998PLC102040

Press release

Indegene reports 4.9% QoQ growth in Revenue, PAT crosses INR 100 crores for the quarter

Bengaluru, India, January 30, 2025: Indegene, a digital-first, life sciences commercialization company, announced financial results for the quarter ended December 31, 2024.

- Achieved revenue of INR 7,204 million in Q3FY25, a growth of 4.9% QoQ
- Achieved PAT of INR 1,097 million, a growth of 19.6% QoQ

Sl. No.	Particulars	Quarter ended		
		Dec 31, 2024	Sept 30, 2024	Dec 31, 2023
1.	Revenue from operations	7,204	6,868	6,734
2.	Revenue from operations (\$ Mn)	85.2	82.0	80.9
3.	YoY revenue growth from operations (%)	7.0%	8.0%	10.3%
4.	EBITDA	1,501	1,267	1,499
5.	EBITDA margin (%)	20.8%	18.4%	22.3%
6.	Profit after tax	1,097	917	988
7.	Profit margin (%)	15.2%	13.4%	14.7%

Indegene also won Deloitte's #TechFast50 2024 Awards (India) in HealthTech for the second successive year.

“We have consistently grown our revenue, maintaining stable and profitable growth, and our Q3FY25 numbers reflect this. We achieved revenue growth of 4.9% QoQ driven by continued traction with large pharma customers and growth momentum with mid-size pharma customers. Our largest customer is continuing to grow, and we are doing a run-rate of a tad below USD 50 million with this customer” said Manish Gupta, Chairman and CEO, Indegene Limited. “We are seeing a steady increase in the revenues from our Top 5 customers, which have grown 3.1% sequentially in this period.”

“Q3FY25 was another successful quarter for Indegene. We improved our EBITDA margin from 18.4% in Q2FY25 to 20.8% in Q3FY25. This was achieved via ongoing productivity improvement through better capacity management and automation, which helped absorb the impact of the annual employee wage hike effective July, fully and beyond”, said Suhas Prabhu, CFO, Indegene Limited. “Our earnings growth continues with PAT margin also increasing to 15.2% for the quarter, in line with our EBITDA performance. PAT has grown from INR 917 million in Q2FY25 to INR 1,097 million in Q3FY25, a growth of 19.6% sequentially.”



About Indegene

Indegene is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient and modern way. Indegene brings together healthcare domain expertise, fit-for-purpose technology and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It's what drives Indegene's team and their purpose to enable healthcare organizations to be future-ready. To learn more, please visit www.indegene.com

For Investor inquiries, please contact:
IR@Indegene.com

For media inquiries, please contact:
Yadunandan K V | yadunandan.kv@indegene.com